drugset
Drugs / HDT-301
last change May 2024 re-read 3 minutes ago

HDT-301

also known as RNA VACCINE MCTI CIMATEC HDT(HDT-301) · VACCINE RNA MCTI CIMATEC HDT (HDT-301)

Messenger RNA (mRNA)

Developed for
COVID-19
Investigated by
C3 Research Associates · HDT Bio · Rainier Clinical Research Center · SENAI CIMATEC

Trials 2

today NCT05132907 · Ph 1 NCT04844268 · Ph 1
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05132907 Jan 2022 → Nov 2023 COVID-19 HDT Bio Completed No outcome recorded
Phase 1 NCT04844268 Jan → Sep 2022 COVID-19 SENAI CIMATEC Unknown No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as HDT-301 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04844268 ↗
1

NCT05132907 ↗
Known as RNA VACCINE MCTI CIMATEC HDT(HDT-301) “RNA VACCINE MCTI CIMATEC HDT(HDT-301) vaccine” NCT04844268 ↗
Known as VACCINE RNA MCTI CIMATEC HDT (HDT-301) “VACCINE RNA MCTI CIMATEC HDT (HDT-301) vaccine” NCT04844268 ↗
Modality Messenger RNA (mRNA) “As a replicating mRNA vaccine” NCT04844268 ↗
Route Intramuscular “Intramuscular injections of 1 µg” NCT04844268 ↗